Bristol Myers Squibb aims to renew its drug portfolio through company acquisitions and investments in research and development that accelerate product launches. The company has 112 clinical trials and 3,200 patients, and is among the top five pharmaceutical companies in Spain for investment in these clinical trials.

“We are going to focus on oncology and hematology, we have 80% of the new molecules in development there, and also on immunological and cardiovascular diseases,” says Sandra Orta, general director of BMS for Spain and Portugal.